What is the share price of Venmax Drugs and Pharmaceuticals Ltd (VENMAX) today?
The share price of VENMAX as on 28th March 2025 is ₹28.52. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Venmax Drugs and Pharmaceuticals Ltd (VENMAX) share?
The past returns of Venmax Drugs and Pharmaceuticals Ltd (VENMAX) share are- Past 1 week: 8.12%
- Past 1 month: 44.18%
- Past 3 months: 74.11%
- Past 6 months: 333.43%
- Past 1 year: 333.43%
- Past 3 years: N/A%
- Past 5 years: 333.43%
What are the peers or stocks similar to Venmax Drugs and Pharmaceuticals Ltd (VENMAX)?
The peers or stocks similar to Venmax Drugs and Pharmaceuticals Ltd (VENMAX) include:What is the market cap of Venmax Drugs and Pharmaceuticals Ltd (VENMAX) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Venmax Drugs and Pharmaceuticals Ltd (VENMAX) is ₹14.37 Cr as of 28th March 2025.What is the 52 week high and low of Venmax Drugs and Pharmaceuticals Ltd (VENMAX) share?
The 52-week high of Venmax Drugs and Pharmaceuticals Ltd (VENMAX) is ₹30.88 and the 52-week low is ₹6.27.What is the PE and PB ratio of Venmax Drugs and Pharmaceuticals Ltd (VENMAX) stock?
The P/E (price-to-earnings) ratio of Venmax Drugs and Pharmaceuticals Ltd (VENMAX) is 205.29. The P/B (price-to-book) ratio is -22.11.Which sector does Venmax Drugs and Pharmaceuticals Ltd (VENMAX) belong to?
Venmax Drugs and Pharmaceuticals Ltd (VENMAX) belongs to the Health Care sector & Pharmaceuticals sub-sector.How to buy Venmax Drugs and Pharmaceuticals Ltd (VENMAX) shares?
You can directly buy Venmax Drugs and Pharmaceuticals Ltd (VENMAX) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Venmax Drugs and Pharmaceuticals Ltd
VENMAX Share Price
28.521.97% (+0.55)
VENMAX Share Price Chart
High
—
Low
—
Returns
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
How to use scorecard? Learn more
VENMAX Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| -19.69 | -22.11 | — |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 49.27 | 6.30 | 0.54% |
VENMAX Analyst Ratings & Forecast
Detailed Forecast —
Forecast data is currently unavailable for this stockPrice Upside
Earnings Growth
Rev. Growth
VENMAX Company Profile
Venmax Drugs and Pharmaceuticals Limited is an India-based company engaged in manufacturing of pharmaceuticals and drugs. The Company is in the business of trading of bulk drugs, intermediates and biotech products.
VENMAX Similar Stocks (Peers)
Compare with peersSUNPHARMA
PE Ratio
44.07
1Y Return
7.04%
Buy Reco %
88.24
CIPLA
PE Ratio
28.93
1Y Return
3.66%
Buy Reco %
72.73
TORNTPHARM
PE Ratio
65.78
1Y Return
24.12%
Buy Reco %
68.00
MANKIND
PE Ratio
51.84
1Y Return
5.39%
Buy Reco %
81.25
DRREDDY
PE Ratio
17.40
1Y Return
7.09%
Buy Reco %
45.16
VENMAX Forecasts
Price
Revenue
Earnings
VENMAX Share Price Forecast
Hmm, looks like data is unavailable here. Please come back after some timeVENMAX Company Revenue Forecast
Hmm, looks like data is unavailable here. Please come back after some timeVENMAX Stock EPS (Earnings Per Share) Forecast
Hmm, looks like data is unavailable here. Please come back after some timeVENMAX
Income
Balance Sheet
Cash Flow
Annual Normal View
VENMAX Income Statement
Annual Normal View
| Financial Year | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | TTM | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 1.93 | 0.38 | 0.00 | 0.15 | 0.47 | 0.35 | 1.98 | 0.42 | 0.20 | 0.60 | ||||||||||
Raw Materials | 1.91 | 0.24 | 0.00 | 0.20 | 0.43 | 0.08 | 0.00 | 0.00 | 0.00 | 1.32 | ||||||||||
| Power & Fuel Cost | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 | |||||||||||
| Employee Cost | 0.07 | 0.06 | 0.05 | 0.10 | 0.22 | 0.06 | 0.01 | 0.03 | 0.02 | |||||||||||
| Selling & Administrative Expenses | 0.09 | 0.09 | 0.10 | 0.16 | 0.17 | 0.13 | 0.11 | 0.10 | 0.05 | |||||||||||
| Operating & Other expenses | -0.00 | 1.33 | 0.08 | -0.08 | -0.09 | 0.24 | 0.01 | 0.05 | 0.03 | |||||||||||
EBITDA | -0.14 | -1.34 | -0.23 | -0.24 | -0.26 | -0.16 | 1.85 | 0.23 | 0.10 | -0.72 | ||||||||||
| Depreciation/Amortization | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | — | ||||||||||
| PBIT | -0.14 | -1.34 | -0.23 | -0.25 | -0.27 | -0.17 | 1.84 | 0.22 | 0.09 | -0.72 | ||||||||||
| Interest & Other Items | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | ||||||||||
| PBT | -0.14 | -1.34 | -0.24 | -0.25 | -0.27 | -0.17 | 1.84 | 0.22 | 0.09 | -0.72 | ||||||||||
| Taxes & Other Items | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 | 0.02 | 0.01 | ||||||||||
| Net Income | -0.14 | -1.34 | -0.24 | -0.25 | -0.28 | -0.17 | 1.84 | 0.22 | 0.07 | -0.73 | ||||||||||
| EPS | -0.27 | -2.56 | -0.46 | -0.48 | -0.53 | -0.32 | 3.51 | 0.42 | 0.13 | -1.39 | ||||||||||
| DPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||||||
| Payout ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
VENMAX Company Updates
FY 2015
Annual report
PDFFY 2016
Annual report
PDFFY 2017
Annual report
PDFFY 2018
Annual report
PDFFY 2019
Annual report
PDFFY 2020
Annual report
PDFFY 2021
Annual report
PDFFY 2022
Annual report
PDFFY 2023
Annual report
PDFFY 2024
Annual report
PDFVENMAX Past Performance & Peer Comparison
Comparing 3 stocks from
Health CarePharmaceuticals
Compare valuation on Screener
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Venmax Drugs and Pharmaceuticals Ltd | 205.29 | -22.11 | — |
| Sun Pharmaceutical Industries Ltd | 44.07 | 6.29 | 0.77% |
| Cipla Ltd | 28.93 | 4.45 | 0.88% |
| Torrent Pharmaceuticals Ltd | 65.78 | 15.89 | 0.87% |
VENMAX Stock Price Comparison
Compare VENMAX with any stock or ETFCompare VENMAX with any stock or ETF
VENMAX
VENMAX Shareholdings
VENMAX Promoter Holdings Trend
Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
VENMAX Institutional Holdings Trend
Increased Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has increased by 4.45%
Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has almost stayed constant
VENMAX Shareholding Pattern
VENMAX Shareholding History
Foreign Institutions
smallcases containing VENMAX stock
Looks like this stock is not in any smallcase yet.
VENMAX Events
VENMAX Dividend Trend
No Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year
VENMAX has not given any dividends in last 5 years
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
VENMAX Dividends
Hmm, looks like data is unavailable here. Please come back after some timeVENMAX Stock News & Opinions
Articles & Videos
Earnings
Venmax Drugs & Pharmaceuticals reports standalone net loss of Rs 0.50 crore in the December 2024 quarter
Net loss of Venmax Drugs & Pharmaceuticals reported to Rs 0.50 crore in the quarter ended December 2024 as against net profit of Rs 0.03 crore during the previous quarter ended December 2023. Sales reported to Rs 0.20 crore in the quarter ended December 2024. There were no Sales reported during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales0.200 0 OPM %-250.000 - PBDT-0.500.04 PL PBT-0.500.04 PL NP-0.500.03 PL Powered by Capital Market - Live
1 month agoCapital Market - Live
Corporate
Venmax Drugs & Pharmaceuticals announces board meeting date
Venmax Drugs & Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 8 February 2025.Powered by Capital Market - Live
1 month agoCapital Market - Live
Corporate
Venmax Drugs & Pharmaceuticals to conduct EGM
Venmax Drugs & Pharmaceuticals announced that an Extra Ordinary General Meeting (EGM) of the Company will be held on 6 February 2025.Powered by Capital Market - Live
2 months agoCapital Market - Live
Corporate
Venmax Drugs & Pharmaceuticals announces board meeting date
Venmax Drugs & Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 11 January 2025.Powered by Capital Market - Live
2 months agoCapital Market - Live
Over the last 5 years, revenue has grown at a yearly rate of 5.92%, vs industry avg of 9.04%
Over the last 5 years, market share stayed at 0%